Autolus Therapeutics plc (AUTL)Healthcare | Biotechnology | London, United Kingdom | NasdaqGS
2.34 USD
-0.02
(-0.847%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 2.34 |
Hot Take ↕ | Aug. 22, 2026, 3:44 a.m. EDT
The investment case for Autolus is currently bifurcated between a speculative short-term trade and a distressed long-term reality. On the immediate horizon, the options market is screaming bullishness; the sheer volume of call open interest at strikes just above the current price suggests traders are positioning for a rapid rally, likely fueled by the upcoming AUCATZYL launch data. This creates a high-conviction setup for a momentum play over the next few weeks, where the stock could test the $2.50 resistance level. However, looking beyond the noise of the options chain, the fundamental picture is starkly deteriorating. The company is trading at a negative forward P/E with no revenue generation, and the long-term price trajectory is catastrophic, having lost over 94% of its value since 2018. While the last year saw a slight recovery, the broader trend remains a deep value trap. The balance sheet, while currently liquid, supports a business that is burning cash with no path to profitability visible in the traditional sense. The massive gap between the analyst mean target of $8.73 and the current price of $2.41 reflects this hope, but the lack of dividends and the severe historical decline suggest that any rally is purely event-driven speculation rather than a correction to intrinsic value. For the long-term investor, the risks of capital destruction outweigh the potential for a turnaround. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.176367 |
| MSTL | 0.176696 |
| AutoETS | 0.179570 |
| AutoARIMA | 0.179700 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 42.94 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.081 |
| Excess Kurtosis | -1.50 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.028 |
| Market Cap | 622,820,352 |
| Forward P/E | -3.73 |
| Website | https://www.autolus.com |
As of Aug. 22, 2026, 3:44 a.m. EDT: Speculators are overwhelmingly bullish on the near term, evidenced by massive open interest in out-of-the-money calls (strikes $1.50 and $2.00) compared to negligible put activity. This 'call-only' positioning suggests a strong bet on a price surge toward the $2.50-$3.00 range within weeks, driven by anticipated catalysts like the AUCATZYL launch. Conversely, the lack of long-dated put volume indicates minimal hedging against a multi-month crash, reinforcing a speculative, directional bias rather than a defensive stance.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.67375886 |
| Address1 | The Mediaworks |
| Address2 | 191 Wood Lane White City |
| All Time High | 53.24 |
| All Time Low | 1.105 |
| Ask | 2.46 |
| Ask Size | 5 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 2,770,660 |
| Average Daily Volume3 Month | 1,913,254 |
| Average Volume | 1,913,254 |
| Average Volume10Days | 2,770,660 |
| Bid | 2.32 |
| Bid Size | 1 |
| Book Value | 5.91 |
| City | London |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United Kingdom |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.34 |
| Current Ratio | 11.054 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 2.355 |
| Day Low | 2.28 |
| Display Name | Autolus Therapeutics |
| Earnings Call Timestamp End | 1,786,451,400 |
| Earnings Call Timestamp Start | 1,786,451,400 |
| Earnings Timestamp | 1,786,451,400 |
| Earnings Timestamp End | 1,794,832,200 |
| Earnings Timestamp Start | 1,794,832,200 |
| Ebitda | -68,942,608 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 1.818 |
| Enterprise To Revenue | -116.21 |
| Enterprise Value | -125,332,080 |
| Eps Current Year | -0.79243 |
| Eps Forward | -0.62662 |
| Eps Trailing Twelve Months | -1.05 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.7951 |
| Fifty Day Average Change | 0.54489994 |
| Fifty Day Average Change Percent | 0.3035485 |
| Fifty Two Week Change Percent | 67.375885 |
| Fifty Two Week High | 2.58 |
| Fifty Two Week High Change | -0.24000001 |
| Fifty Two Week High Change Percent | -0.09302326 |
| Fifty Two Week Low | 1.175 |
| Fifty Two Week Low Change | 1.165 |
| Fifty Two Week Low Change Percent | 0.99148935 |
| Fifty Two Week Range | 1.175 - 2.58 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,529,674,200,000 |
| Float Shares | 33,904,120 |
| Forward Eps | -0.62662 |
| Forward P E | -3.7343206 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 752 |
| Fullday Change | -0.02 |
| Fullday Change Percent | -0.847457 |
| Fullday Price | 2.34 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -26,476,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.18080999 |
| Held Percent Institutions | 0.63424 |
| Implied Shares Outstanding | 266,162,540 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom. |
| Long Name | Autolus Therapeutics plc |
| Market | us_market |
| Market Cap | 622,820,352 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_562879769 |
| Most Recent Quarter | 1,546,214,400 |
| Net Income To Common | -53,279,500 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 628,143,594 |
| Number Of Analyst Opinions | 8 |
| Open | 2.35 |
| Operating Margins | -65.70746 |
| Payout Ratio | 0.0 |
| Phone | 44 20 3829 6230 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 2.34 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 2.36 |
| Price Eps Current Year | -2.9529421 |
| Price Hint | 4 |
| Price To Book | 0.39593908 |
| Price To Sales Trailing12 Months | 577.48755 |
| Profit Margins | 0.0 |
| Quick Ratio | 10.317 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.11111 |
| Region | US |
| Regular Market Change | -0.02 |
| Regular Market Change Percent | -0.847457 |
| Regular Market Day High | 2.355 |
| Regular Market Day Low | 2.28 |
| Regular Market Day Range | 2.28 - 2.355 |
| Regular Market Open | 2.35 |
| Regular Market Previous Close | 2.36 |
| Regular Market Price | 2.34 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 1,436,829 |
| Return On Assets | -0.22275 |
| Return On Equity | -0.29621 |
| Revenue Per Share | 0.028 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 266,162,540 |
| Shares Percent Shares Out | 0.0394 |
| Shares Short | 10,484,939 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 15,142,908 |
| Short Name | Autolus Therapeutics plc |
| Short Percent Of Float | 0.060700003 |
| Short Ratio | 4.28 |
| Source Interval | 15 |
| Symbol | AUTL |
| Target High Price | 11.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 8.725 |
| Target Median Price | 9.5 |
| Total Cash | 217,450,000 |
| Total Cash Per Share | 5.524 |
| Total Debt | 0 |
| Total Revenue | 1,078,500 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.05 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.59855 |
| Two Hundred Day Average Change | 0.74144995 |
| Two Hundred Day Average Change Percent | 0.46382657 |
| Type Disp | Equity |
| Volume | 1,436,829 |
| Website | https://www.autolus.com |
| Zip | W12 7FP |